文献速递系统性红斑狼疮

系统性红斑狼疮炎症性神经精神表现的治系统综述

Management of inflammatory neurologic and psychiatric manifestations of systemic lupus erythematosus: A systematic review.
PubMed 文献 · Semin Arthritis Rheum · 2020-12-17

该系统综述检索了1990年至2019年3月的文献,纳入90项研究,评估炎症性神经精神狼疮(NPSLE)的治疗证据。糖皮质激素被接受为一线治疗但证据水平低至中等,环磷酰胺有中等证据支持,难治性疾病中利妥昔单抗和自体干细胞移植有有限证据支持,整体缺乏高质量试验数据。

要点

  • 糖皮质激素为NPSLE一线治疗,证据水平低至中等。
  • 环磷酰胺获中等证据支持,源于多项研究一致数据及部分试验数据。
  • 难治性疾病中利妥昔单抗和自体干细胞移植分别有低至中等和有限证据支持。

核心结论

  • 炎症性NPSLE有多种治疗选择,包括全身性、生物制剂和介入治疗,但目前缺乏高质量试验数据以指导明确推荐。

研究设计与样本

  • 检索Medline、Embase、CINHAL和Cochrane CENTRAL从1990年至2019年3月底,纳入临床试验、观察性研究或病例系列(≥5例患者)且具备足够治疗和结局数据的NPSLE研究。

主要发现

  • 共识别7222项研究,纳入90项,其中仅2项随机对照试验和1项 pilot 研究。
  • 治疗类别包括糖皮质激素(14项研究)、环磷酰胺(18项)、合成DMARDs(7项)、生物制剂(14项)、治疗性血浆置换(6项)、静脉免疫球蛋白(2项)、自体干细胞移植(3项)、其他治疗(8项)、联合治疗(6项)、分组结局数据研究(5项)和特定治疗关联的观察性研究(7项)。

关键数值与推荐

  • 糖皮质激素被接受为NPSLE一线治疗,有低至中等证据支持其获益。
  • 中等证据基于多项研究一致数据和部分试验数据支持环磷酰胺治疗NPSLE。
  • 有限数据支持某些合成DMARDs如霉酚酸酯、硫唑嘌呤和鞘内甲氨蝶呤。
  • 难治性疾病中,低至中等证据支持利妥昔单抗治疗,有限证据支持自体干细胞移植后的获益。
  • 辅助治疗方面,有限证据支持加用血浆置换、静脉免疫球蛋白和羟氯喹。

临床怎么用

  • 糖皮质激素作为NPSLE一线治疗,环磷酰胺在有中等证据支持下用于治疗。
  • 难治性病例可考虑利妥昔单抗或自体干细胞移植,但证据有限。
  • 辅助治疗中血浆置换、静脉免疫球蛋白和羟氯喹有有限证据支持。

局限性

  • 临床试验明显缺乏,仅2项随机对照试验和1项 pilot 研究,缺乏高质量试验数据指导明确推荐。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The neurological and psychiatric manifestations of systemic lupus erythematosus (NPSLE) are a heterogeneous group of conditions with variable clinical presentation and significant morbidity and mortality. OBJECTIVES: Our aim was to comprehensively assess and present the evidence for treatments used in the management of inflammatory NPSLE. METHODS: Medline, Embase, CINHAL and Cochrane CENTRAL were searched from 1990 to end of March 2019 using key words that related to NPSLE and treatment. Included studies comprised clinical trials, observational studies or case series with ≥5 patients and sufficient data related to treatment and outcome in NPSLE patients. RESULTS: There were 7222 studies identified in the search, of which 90 were included in the review. There was a notable paucity of clinical trials, with only two randomised controlled trials and one pilot study. Treatment categories included corticosteroids (14 studies), cyclophosphamide (18 studies), synthetic DMARDs (7 studies), biologic therapies (14 studies), therapeutic plasma exchange (6 studies), intravenous immunoglobulin (2 studies), autologous stem cell transplant (3 studies), other therapies (8 studies), combination therapies (6 studies), studies with grouped outcome data (5 studies) and observational studies with therapy-specific associations (7 studies). Corticosteroids are accepted as first line treatment in NPSLE and there is low-moderate evidence supporting their benefit. Moderate evidence, based on consistent data in numerous studies and some trial data, supports the use of cyclophosphamide in the treatment of NPSLE. Limited data support some synthetic DMARDs such as mycophenolate, azathioprine and intrathecal methotrexate. In refractory disease, low-moderate evidence supports rituximab therapy and limited evidence supports benefit following autologous stem cell transplant. Regarding adjuvant treatments, limited evidence favours addition of plasma exchange, intravenous immunoglobulin and hydroxychloroquine. There exists very limited data for other therapies. CONCLUSION: There are multiple therapeutic options for the management of inflammatory NPSLE including systemic, biologic and interventional therapies; however, currently there is a paucity of high-quality trial data to guide firm recommendations. In order to better understand the optimal treatment of NPSLE and its different subtypes, further well-designed clinical trials are needed.

来源:Semin Arthritis Rheum,查看原文。版权归原作者所有。

引用

  1. Papachristos DA, Oon S, Hanly JG, et al. Management of inflammatory neurologic and psychiatric manifestations of systemic lupus erythematosus: A systematic review. Semin Arthritis Rheum. 2020. PMID: 33360230. doi:10.1016/j.semarthrit.2020.12.004

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。